

## Subject Index to Volume 20 (2003)

- A**
- Abbreviated New Drug Application (ANDA), 531
  - ABCB1, 1141
  - ABC-B11, 537
  - ABC transporter, 324, 537
  - Abetalipoproteinemia, 368
  - Ablation, 879
  - Absorption, 31, 177, 900, 1141, 1595, 1668, 1766, 1984
  - Absorption, intestinal, 1163, 1192, 1200, 1210, 1674
  - Absorption, lymphatic, 1156
  - Absorption, ocular, 1409
  - Absorption, oral, 397, 1149, 1674, 1961
  - Absorption, percutaneous, 270, 275, 1113
  - Absorption, pulmonary, 545, 1551
  - Absorption rate, 1409
  - Absorption rate, duodenal, 552
  - Absorption rate limit, 848
  - Absorption site, 1595
  - Absorptive quotient, 1210
  - Absorptive transport, 1192, 1200, 1210
  - Accumulation assay, 1177
  - Acetylsalicylic acid, 471
  - Acrylic polymers, 1970
  - Acryloyl-hydroxyethyl starch, 452
  - Activated endothelial cells, 64
  - Activation, 1001
  - Active transport, 1125
  - Acyclovir, 584
  - Adaptive neural fuzzy inference system, 143
  - Additives, 283
  - Adenosine kinase, 843
  - Adenosine triphosphatase (ATPase), 1581
  - Adenosine triphosphate (ATP), 1581
  - Adenovirus, 1444
  - ADEPT (antibody-directed enzyme prodrug therapy), 423
  - Adhesion force, 508, 804
  - Adjuvants, 247
  - Adsorption, 247, 926, 1466
  - Aerosol, 2011
  - Aerosol characterization, 788
  - Aerosol delivery, 2028
  - Aerosol Solvent Extraction System (ASES), 2028
  - Aerosolization, 252, 1485
  - Aerosols, 442, 2011
  - Agatoxins, 897
  - Agglutinins, 833, 1258
  - Aggregation, 693, 1655, 1721, 1873
  - Aging, 1713
  - Airway epithelium, 545, 779
  - Alacepril thiolesterase, 1309
  - Albumin, 857
  - Albumin, bovine serum, 81, 303
  - Albumin, human serum, 684
  - Alcohols, 471
  - Algorithms, 1401
  - Alkylcarbonyloxymethyl prodrugs, 639
  - Alum adjuvant, 969
  - Alveolar epithelial cells, 1231
  - Amino acid ester prodrugs, 1381
  - Amino acid transporters, 1125
  - Amino acids, 448
  - Aminoreban EN®, 1932
  - Amorphous, 1430, 1647
  - Amorphous lactose, 1039
  - Amorphous solid dispersion, 810
  - Amorphous solids, 308
  - Amorphous state, 1417
  - Amphiphiles, 465
  - Amphiphilic  $\beta$ -cyclodextrins, 117
  - Amphiphilic copolymers, 1284
  - Anhydride prodrugs, 205
  - Antiapoptotic cellular defense, 351
  - Antibody-directed enzyme prodrug therapy (ADEPT), 423
  - Antibody-enzyme conjugates, 423
  - Anticancer drugs, 1558
  - Anticholinergics, soft, 1681
  - Anticonvulsant activity, 1293
  - Antiestrogen, 1063
  - Antigen-presenting cells, 1239
  - Antimicrobial activity, 442
  - Antimicrobial agents, 1149
  - Antimicrotubules, 45
  - Antioxidant response element, 1351
  - Antipyrine, 187
  - Antisense oligonucleotides, 351, 1565
  - Antitubercular drugs, 1760
  - Antitumor activity, 448
  - Antiviral activity, 448
  - Apolipoprotein B, 368
  - Apomorphine, 653
  - Apoptosis, 45, 351, 889, 962, 1485
  - Aqueous form, 1952
  - Aqueous soluble compounds, 1820
  - Aqueous solutions, 465, 1325, 1977
  - Arginine-based surfactants, 1697
  - Array, 257
  - Arthrocentesis, 605
  - Artificial neural networks, 1760
  - ASES (Aerosol Solvent Extraction System), 2028
  - Atenolol, 1141, 1946
  - Atmospheric freeze-drying (ATMFD) process, 485
  - Atomic force, 508
  - Atomic force microscopy, 479, 804
  - Azido-3'-deoxythymidine, 957
  - Azido-3'-deoxythymidine-monophosphate pronucleotide, 448
  - Azithromycin, 624
- B**
- Baclofen esters, 772
  - Bacteria, colonic, 429
  - Barbiturates, 864
  - Bcl-2 family proteins, 351, 373, 889
  - Benzoic acid, 471
  - Best practices, 1885
  - BET monolayer, 308
  - Beta-blockers, 1496, 1946
  - BH3 peptide, 889
  - Bicarbonate buffer system, 1641
  - Bifonazole, 117
  - Bile acid sequestrants, 460
  - Bile salts, 597, 900
  - Biliary excretion, 31, 448, 910
  - Binary mixtures, 1939
  - Binding, 833, 1009, 1523
  - Binding, nonspecific protein, 1015
  - Binding affinity, 360
  - Binding parameters, 1702
  - Binding sites, 537
  - Bioadhesion, 1093
  - Bioanalytic assay, 1885
  - Bioavailability, 24, 931, 1093, 1184, 1474, 1551, 1626, 1668, 1846, 1984
  - Bioavailability, ocular, 584
  - Bioavailability, oral, 448
  - Biochanin A, 1184
  - Biocompatibility, 1533
  - Bioconversion, xenobiotic, 1113
  - Biodegradability, 884, 2011
  - Biodegradable polymers, 149
  - Biodistribution, 96, 1239
  - Bioequivalence, 103
  - Bioequivalence, scaled average, 382
  - Biologic activity, 818
  - Biologic matrices, 1885
  - Biomarkers, 996
  - Biopharmaceutics, 1149
  - Biopharmaceutics, molecular, 1730, 1738, 1746
  - Biopharmaceutics Classification System, 749, 1917, 1961
  - Biorelevant dissolution media, 1641
  - Bisphosphonates, 978
  - Bitter taste, 1932
  - Blood-brain barrier, 409, 618, 705, 772, 904, 1170, 1225, 1394, 1607, 1772
  - Blood-brain barrier permeability, 390
  - Blood-cerebrospinal fluid barrier, 714, 720
  - Blood-placental barrier, 38
  - Blood-retinal barrier, 1357
  - Blood sampling, 1474
  - Bone targeting, 978
  - Bovine serum albumin, 81, 303
  - Bowman-Birk inhibitor, spermine-conjugated, 1908
  - Brain, 409, 1713, 1779
  - Brain microvessel endothelial cell monolayers, 390
  - Brain perfusion, 904, 1772
  - Brain transport, 1607
  - Brain uptake, 1225
  - Breast cancer, 351, 1063
  - Brefeldin, 1231
  - Brij, 1772
  - Bronchial epithelial cell lines, 545
  - Brush-border membrane vesicles, 38, 1133
  - B7 costimulatory molecules, 1239
  - Budesonide, 1690
  - Buffer systems, 1641
  - Buffers, 802
  - Buffers, high-pH, 1437
  - Burst, initial, 149
  - Buspiron, 187
- C**
- Caco-2 artificial membranes, 833
  - Caco-2 cell homogenates, 1381
  - Caco-2 cell permeability, 1149
  - Caco-2 cells, 3, 110, 169, 187, 373, 397, 569, 848, 1085, 1119, 1141, 1184, 1200, 1389, 1543, 1674, 1738, 1812, 1961
  - Caco-2 permeability, 177
  - Caco-2 subclones, 161
  - Caco-2:Ht29GluH coculture, 569
  - Calcein-AM, 1170
  - Calcitonin, 73, 1989
  - Calcium-channel blockade, 897
  - Calorimetry, 500
  - Calorimetry, differential scanning, 283, 1430, 1926
  - Calorimetry, isothermal, 1430
  - Calu-1 cells, 779
  - Calu-3 cells, 788
  - Camptothecin, 1031
  - Canalicular membrane vesicles, 89
  - Cancer, 351, 843, 889
  - Cancer cells, 423
  - Canicular multispecific organic anion transporter (cMOAT), 89
  - Carbomer hydrogels, 435
  - Carbonylation, 1713
  - Carboxylesterase, 1309
  - Carboxylic acid group, 205
  - Carcinogenesis, 1908
  - Carnitine transport, 1133
  - Carrier-mediated transport, 390
  - Carrier proteins, 591
  - Carriers, 297
  - Casein, 611, 1746
  - Cassette dosing, 1409
  - Catanionic mixtures, 1661
  - Catheters, 328
  - Cationic drugs, 1858
  - Cationic liposomes, 962
  - Cationic microparticles, 247
  - Cations, organic, 597
  - Caveolae, 545
  - CD21 receptors, 360
  - CD protein, 1539
  - Cefazolin, 283, 937
  - Cell culture models, 373, 569
  - Cell cultures, 545, 1357, 1409
  - Cell handling, 624
  - Cell transfection, 2021
  - Cell transplantation, 1103
  - Cellular processing, 229
  - Cellular uptake, 229
  - Central nervous system drug delivery, 409
  - Cerebral cortex, 897

- Cerebral perfusion flow, 705  
 Cetyltrimethylammonium bromide (CTAB), 247  
 Characterization, 161  
 Chemical enhancers, 264  
 Chemical mixtures, 275  
 Chemoinformatics, 843  
 Chemoprevention, 1351  
 Chemosensitization, 1581  
 Chemotherapeutic activity, 728  
 Chemotherapeutic agents, 843  
 Chemotherapy, 1337  
 Chemotherapy, personalized, 843  
 Chicken hen egg lysozyme, 591  
 Chiral separation, 1881  
 Chitosan, 1812  
 Chloramine-T, 684  
 Chloroquine, 624  
 Cholestasis, 537  
 Cholesterol biosynthesis, 1908  
 Choroid plexus, 714, 720  
 Chromatography, gas, 275, 337  
 Chromatography, inverse gas, 1647  
 Chromatography, liquid, 1820  
 Chromatography, liquid high performance, 693, 1881  
 Chronic renal insufficiency, 1600  
 Chymotrypsin, 611, 1746, 1873  
 CI-1041, 797  
 Cimetidine, 632  
 c-Jun N-terminal kinase (JNK1), 1351  
 Clinical trial simulation, 1752  
 Clobetasol propionate, 1835  
 Clotrimazole, 117  
 Clotting, 693  
 cMOAT (canicular multispecific organic anion transporter), 89  
 CMV (cytomegalovirus), 89  
 Cocaine, 1827  
 CODES™ system, 429  
 Coefficients, 143, 275, 772, 857, 1325, 1502, 1858  
 Coencapsulation, 1730  
 Colchicine, 1607  
 Colloidal carriers, 1274, 1539  
 Colon, 429, 1444  
 Colon cancer cells, 1249  
 Colon targeting, 303  
 Colorectal cancer cell lines, 324  
 Combinatorial approach, 1302  
 Combinatorial libraries, 1258  
 Compactibility, direct, 515  
 Compartmentalization, 728  
 Compensation effect, 471  
 Composite, 996  
 Composite markers, 996  
 Composite particles, 1039  
 Compound profiling, 1170  
 Computational biopharmaceutics, 1794  
 Computer-assisted trial design, 1752  
 Computer simulation, 96, 1977  
 Concentration-dependent effects, 1984  
 Concentrative nucleoside transporter, 319  
 Conformational stability, 1325  
 Conjugates, 360, 423, 465, 714, 728  
 Conjugation, 978, 1908  
 Conjugation, site-specific, 818, 826  
 Conotoxins, 897  
 Consensus document, 1885  
 Contact area, 257, 508  
 Controlled release, 96, 452, 1055, 1466, 1533, 1730, 1864, 1989, 2008  
 Convective transport, 96  
 Copolymers, 360, 668, 884, 1085, 1284, 1558, 1995, 2008  
 Corneal epithelium, 1409  
 Corticosteroids, 1835  
 Cosolvents, 1984  
 Cremophor® EL, 1085, 1302  
 Crystal growth, 1417  
 Crystal nucleation, 1417  
 Crystalline nanoparticles, 479  
 Crystallization, 283, 660, 802, 1939  
 Crystals, sterically stabilized, 297  
 CTAB (cetyltrimethylammonium bromide), 247  
 CTLA4Ig, 1239  
 C225, 826  
 Curing, 1970  
 Cyanophenol, 632  
 Cyclic voltammetry, 1317  
 Cyclodextrin, 1626  
 Cyclooxygenase-2 (COX) inhibitors, 1485  
 Cyclophosphamide, 557  
 Cyclosporin A, 126, 749, 910, 1163  
 Cyclosporine, 252, 1009  
 CYP, *see* Cytochrome P450  
 Cysteine mutation, 684  
 Cytochrome P450, 81, 1591, 1600  
 Cytochrome P450 3A, 24, 324  
 Cytochrome P450 3A1, 745  
 Cytochrome P450 3A2, 745  
 Cytochrome P450 3A4, 557, 745, 1119, 1401  
 Cytochrome P450 2B6, 557  
 Cytochrome P450 induction, 1373  
 Cytomegalovirus (CMV), 89  
 Cytoplasmic delivery, 212  
 Cytosol, 779  
 Cytotoxicity, 360, 1485, 1543
- D**
- Danazol, 485  
 Daunomycin, 1163  
 Deacetylalacepril, 1309  
 Decision tree, 1634  
 Degradation, 149  
 Degradation kinetics, 149  
 Degradation pathways, 779  
 Dehydration, 802, 1926  
 Delivery, *see* Drug delivery  
 Denaturation, 1325  
 Dendrimer surfaces, 1543  
 Dendritic cells, 221  
 Deoxyribonucleic acid (DNA), 328, 1452  
 Deoxyribonucleic acid (DNA) delivery, 247  
 Deoxyribonucleic acid (DNA) (DNA)/liposome complexes, 1452  
 Deoxyribonucleic acid (DNA) vaccine, 16  
 Dependence, 257  
 Dephosphorylation, 1838  
 Deposition, 252, 442  
 Dermal penetration, 1827  
 Desethyloxybutynin, 103  
 Deslorelin, 779  
 Desorption rate, 1409  
 Dexamethasone, 1163  
 Dextran, 1284  
 Dextran-methylprednisolone succinate, 198  
 Dextran prodrugs, 198, 1001  
 Diabetes, 345, 1995, 2008  
 Dialysis, equilibrium, 1015  
 Dicumarol, 1093  
 Diet, elemental, 1932  
 Diethylaminopropyl amine-poly(vinyl alcohol)-grafted-poly(lactide-co-glycolide), 2011  
 Differential pulse voltammetry, 292  
 Differential scanning calorimetry, 283, 1430, 1926  
 Diffractometry, x-ray low-temperature, 660  
 Diffractometry, x-ray powder, 283, 1851  
 Diffusion, 857  
 Diffusion cell experiments, 639  
 Diffusion layer model, 406  
 Diffusion rate, 1055  
 Diffusive transport, 96  
 Diffusivity, 1502  
 Digestion products, 1746  
 Digoxin, 38, 169, 552, 1163, 1184  
 Dihydropyridine, 292  
 Dihydropyridine derivatives, 292  
 Dimethyl-β-cyclodextrin, 1551  
 Dimethylsulfoxide (DMSO), 292  
 Dinitrophenol, 1317  
 Dipeptide transporter, 1911  
 Direct compaction, 515  
 Direct ultraviolet compound analysis, 1961  
 Disintegration, 460, 1668  
 Disodium hydrogen phosphate, 802  
 Dispersion, solid, 135, 1047  
 Dispersion models, 1452  
 Disposition kinetics, 368, 1846  
 Dissolution, 485, 797, 1047, 1641, 1668, 1674  
 Dissolution media, 1641  
 Dissolution rate, 810  
 Dissolution time, 406  
 DMP 504, 460  
 DMSO (dimethylsulfoxide), 292  
 DNA (deoxyribonucleic acid), 328, 1452, 1730, 1779  
 DNA (deoxyribonucleic acid) delivery, 247  
 DNA (deoxyribonucleic acid) vaccine, 16  
 DNA(deoxyribonucleic acid)/liposome complexes, 1452  
 Dodecahydrate, 802  
 Dogs, 460, 605, 1460  
 Dosage, 460  
 Dosage, gastroretentive, 1466  
 Dose, 1574  
 Dose estimation, 1752  
 Dose response, 591  
 Dose/solubility ratio, 406, 1917  
 Down regulation, 1600  
 Down-regulation, 1600  
 Doxorubicin, 58, 351, 417, 826, 904, 1192, 1485, 1558, 1581  
 Drug absorption, *see* Absorption  
 Drug binding, 409  
 Drug bioavailability, *see* Bioavailability  
 Drug carrier systems, 1619  
 Drug delivery, 103, 149, 705, 879, 978, 1103, 1337, 1466, 1533, 1558, 1827, 1864, 2011  
 Drug delivery, central nervous system, 409  
 Drug delivery, colon-specific, 303  
 Drug delivery, hepatic, 198  
 Drug delivery, intestinal, 110  
 Drug delivery, intravitreal, 576  
 Drug delivery, lectin-mediated, 833  
 Drug delivery, lipophilic, 1085  
 Drug delivery, ocular, 96, 584  
 Drug delivery, oral, 1071  
 Drug delivery, protein, 1231  
 Drug delivery, pulmonary, 788, 1231  
 Drug delivery, targeted, 1523  
 Drug delivery, targeted liposomal, 417  
 Drug delivery, transdermal, 257, 264, 1612, 1619, 1946  
 Drug delivery systems, 833, 2001, 2026  
 Drug delivery systems, colon-specific, 429  
 Drug delivery systems, oral, 931  
 Drug delivery systems, soft nanoprecipitated, 2036  
 Drug delivery systems, transnasal, 1838  
 Drug interactions, 537, 1389, 1401  
 Drug loading ratio, 1864  
 Drug metabolism, 81  
 Drug monitoring, therapeutic, 1508  
 Drug products, 531  
 Drug profile, 1835  
 Drug release, 988  
 Drug release rate, 1055  
 Drug substance, 531  
 Drug transport, 169, 373, 632, 1192, 1337, 1357, 1607  
 Drug transport, in vitro, 1690  
 Drug transport, intestinal, 3, 373  
 Drug transport, intestinal lymphatic, 1460  
 Drug transport, pH-dependent bidirectional, 1141  
 Drugs, 1119  
 Drugs, highly-variable, 382  
 Dry powder coating, 1970  
 Duodenum, 552
- E**
- EDTA (ethylenediamine tetraacetic acid), 73  
 Efflux, 161, 749, 900, 904  
 Efflux, active, 1141  
 Efflux, passive, 1141  
 Efflux ratio, 1200  
 Efflux transport, 720, 1394  
 Eisai hyperbilirubinemic rats, 31  
 Elastic vesicles, 1619  
 Electrical resistance, 1690  
 Electrogenated superoxide ions, 292  
 Electron spin resonance, 1274  
 Electroosmosis, 646, 1946  
 Electroporation, 879, 1946  
 Electrostatic spinning, 810  
 Elemental diet, 1932

- Emulsifiers, 1864  
 Emulsifying wax, 1772  
 Emulsion polymerization, 1786  
 Emulsions, water-in-oil, 130  
 Enantioselective analysis, 1881  
 Encapsulation, 442, 1873  
 Endo-lysosomal escape, 212  
 Endocytosis, 212, 1812  
 Endothelial cell monolayers, 390  
 Endothelial cells, blood-brain barrier, 904  
 Endothelial cells, inflamed, 64  
 Endothelin antagonists, 89  
 Enhancers, chemical, 264  
 Enthalpy, 471  
 Enzyme activity, 1373  
 Enzyme inhibition, 1746  
 Enzyme inhibitors, 1989  
 Enzymosomes, 423  
 E100, 1533  
 Epidermal growth factor, 818  
 Epidermal growth factor liposomes, 229  
 Epidermal growth factor receptors, 826, 833  
 Epidermal immunization, 969  
 Epidermal retention, 270  
 Epidermis, 1113, 1502  
 Epilepsy, 1293  
 Epithelial cells, 779, 788  
 Epithelium, airway, 545  
 Epithelium, intestinal, 397, 1210  
 Epithelium, nasal, 153, 1125  
 Epithelium, renal, 319  
 Epitopes, 360, 591  
 Epoetin, 1903  
 Equations, 639  
 Equilibrium dialysis, 1015  
 Erythropoietin, 1903  
 E-selectin, 64  
 Esterification, 1381  
 Esteron® Solution, 1827  
 Estradiol-17 $\beta$ -glucuronide, 720, 1394  
 Ethylenediamine tetraacetic acid (EDTA), 73  
 Etoposide, 904  
 Eudragit® E100, 135  
 Eudragit® RS, 1970  
 Eutectic, 1939  
 Ewing sarcoma, 1565  
 Excipients, 515  
 Excretion, 448, 910  
 Excretion, hepatobiliary, 89  
 Exocytosis, 212  
 Expression, 765  
 Expression level, 1119  
 Exsorption, 910  
 Extended release, 1970  
 Extrusion, 1047
- F**
- FaDu cells, 957  
 Fasting state, 1460  
 Fatty acids, 1612  
 Felodipine, 292  
 Fermentation, 429  
 Fetuin, 978  
 Fexofenadine, 1177  
 Fiber, membrane-coated, 275  
 Fibrillation, 73  
 Fictive temperature, 1430  
 Filler-binders, 515  
 Flavonoids, 169, 1184  
 Flavors, 1932
- Flow-promoting agents, 804  
 Flowability, 804  
 Floxuridine, 1381  
 Flufenamic acid, 1851  
 Fluorescein, 714  
 Fluorescein hapten, 591  
 Fluorescence, silver nanoparticle-enhanced, 833  
 Fluorescence, x-ray, 435  
 Fluorescence lifetime, 926  
 Fluorescence quenching, 1721  
 Fluorescence spectrum, 926  
 Fluorescent substrates, 537, 1738  
 Fluorinated esters, 918  
 Fluorouracil, 639  
 Flux, 639  
 Folate conjugates, 714  
 Folate receptors, 417, 714  
 Folded sheets mesoporous material (FSM-16), 926  
 Formulations, 969, 1302, 1325  
 Formulations, liquid, 1952  
 Formulations, lyophilized, 1655, 1952  
 Fraction dose absorbed, 1766  
 Free bases, 270  
 Freeze-drying, 283, 485, 494, 802  
 Frozen solutions, 660  
 Fruit juice, 169  
 FSM-16 (folded sheets mesoporous material), 926  
 Fully human monoclonal antibody, 1952  
 Function, 765  
 Fumidipine, 292  
 Fuzzy logic, 143
- G**
- Gabapentin, 897  
 Gadolinium chelates, 2001  
 Galactosidase, 16  
 Galactosidase assay, 2021  
 Galactosylation, 1452  
 Gallic acid, 1258  
 Gas chromatography, 275, 337  
 Gas sparging, 1641  
 Gastric emptying, 1668  
 Gastric-retention tablets, 2001  
 Gastrointestinal excretion, 910  
 Gastrointestinal flow, 1766  
 Gastrointestinal transit, 1984  
 Gastroretentive dosage forms, 1466  
 Gels, 1661  
 Gemini surfactants, 1697  
 Gene delivery, 738, 1103, 1444, 1452, 1730  
 Gene delivery, intestinal, 569  
 Gene delivery systems, 884  
 Gene delivery vehicles, 1995  
 Gene expression, 324, 1373  
 Gene expression, quantitative, 1373  
 Gene expression, transporter, 1119  
 Gene expression profiles, 843, 996  
 Gene therapy, 328, 879, 1444, 1779, 1995  
 Gene therapy toxicity trials, 1779  
 Gene transfection, 738, 884  
 Gene transfer, 345, 576  
 Genetic algorithm, 1401  
 Genomics, 1373
- Genotype, 552  
 Geometric structure, 804  
 G418, 373  
 Glass transition, 1437, 1655  
 Glass transition temperature, 308, 873, 1430, 1647  
 Glassy pharmaceuticals, 308  
 Glioblastoma cells, 1804  
 Glioma, 738  
 Glucocorticoids, 1794  
 Glucose, 873  
 Glucuronides, 465  
 Glutathione, reduced, 931, 1989  
 Glycine, 283  
 Glycoprotein, 978  
 p-Glycoprotein, 38, 45, 161, 545, 597, 749, 757, 772, 900, 904, 910, 1085, 1141, 1170, 1177, 1184, 1200, 1210, 1225, 1595, 1607, 1794  
 p-Glycoprotein inhibitor, 24  
 p-Glycoprotein-mediated efflux pump, 24  
 p-Glycoprotein substrate drugs, 1163  
 Glycosylation, 319  
 Glycylsarcosine, 1389  
 Gradient, 257  
 Granulation, 1851  
 Granulocyte colony stimulating factor, 1231  
 Grapefruit, 169  
 Growth factor delivery, 1103  
 Gustatory sensation, 1932
- H**
- Halofantrine, 1460  
 Headspace analysis, 337  
 Heart, 58  
 Heart disease, 1908  
 Heat, 1039  
 HEK293 cells, 1911  
 HeLa cells, 1738  
 Hemolysis, 117, 1697  
 Hen egg lysozyme, 591  
 Heparin, low-molecular-weight, 931  
 Hepatic delivery, 198  
 Hepatic disposition, 1452  
 Hepatic failure, 765  
 Hepatic metabolism, 1591, 1600  
 Hepatitis B surface antigen, 969  
 Hepatobiliary excretion, 89  
 Hepatocytes, 89, 557, 1568  
 Heterogenous compounds, 187  
 High hydrostatic pressure, 674, 2026  
 High-throughput, 1302, 1713, 1961  
 Highly-variable drugs, 382  
 Higuichi law, 988  
 Histidine, 1911, 1952  
 Hollow filler-binders, 515  
 HPLC (liquid high performance chromatography), 693, 1881  
 HPMA (hydroxypropylmethylacrylamide), 728  
 HPMA (hydroxypropylmethylacrylamide) copolymer conjugates, 360  
 HPMC (hydroxypropyl methylcellulose), 1047
- Human, 545, 557, 646, 653, 684, 728, 957, 1389, 1466, 1595, 1612, 1690, 1721, 1804, 1932, 1952, 2028  
 Human colorectal cancer cell lines, 324  
 Human intestinal fluid, 900  
 Human nasal epithelium, 1125  
 Human skin cultures, 1113  
 Hydration, 257  
 Hydration limit, 308  
 Hydrogels, 303, 435, 884  
 Hydrogels, thermosensitive, 1995  
 Hydrolase, 1309  
 Hydrolysis, 1381  
 Hydrolysis, E-ring, 1031  
 Hydrophilic drugs, 264  
 Hydrophilic macromolecules, 153  
 Hydrophobic drugs, 264  
 Hydrostatic pressure, 2036  
 Hydrotropic agents, 1022  
 Hydroxyethyl starch, 452  
 Hydroxymidazolam, 757  
 Hydroxypropyl methylcellulose (HPMC), 1047  
 Hydroxypropylmethylacrylamide (HPMA), 728  
 Hydroxypropylmethylacrylamide (HPMA) copolymer conjugates, 360  
 Hydroxyzine, 187  
 Hyponatremia, 937  
 Hypothermia, 58  
 Hypoxanthine, 1804
- I**
- Ibuprofen, 205, 500  
 Idarubicin, 58  
 Immortalized cell lines, 1357  
 Immunoassay, 1885  
 Immunoconjugates, 64, 826  
 Immunoenzymosomes, 423  
 Immunogenicity, 1903  
 Immunoliposomes, 64, 423, 1249, 1779  
 Immunosuppressive effects, 198  
 In situ blood-brain barrier transport, 1772  
 In situ brain perfusion, 904, 1607  
 In situ monitoring, 1851  
 In vitro, 64, 103, 275, 297, 390, 442, 1071, 1558  
 In vitro application, 1835  
 In vitro assessment, 705  
 In vitro characterization, 1239  
 In vitro comparison, 1249  
 In vitro disintegration, 460  
 In vitro drug transport, 1690  
 In vitro gene transfection, 738  
 In vitro-in vivo correlation, 857, 864, 1674  
 In vitro models, 788, 1357  
 In vitro P-glycoprotein function, 765  
 In vitro permeability, 1820  
 In vitro permeation studies, 1409  
 In vitro polarized transport, 1125  
 In vitro screening, 1177  
 In vitro screening model, 324  
 In vitro simulation, 1926  
 In vitro tissue distribution, 857, 864  
 In vitro transcellular transport, 1163

- In vivo, 64, 103, 247, 429, 435, 1071, 1239, 1558  
 In vivo assessment, 705, 931, 1989, 2001  
 In vivo disintegration, 460  
 In vivo oxidative damage, 684  
 In vivo p-glycoprotein function, 765  
 In vivo saturation, 1607  
 In vivo stratum corneum, 632  
 In vivo tissue distribution, 857, 864  
 In vivo transdermal delivery, 1496  
 Inactivation, 1655  
 Inclusion complexes, 117, 1626  
 Increased throughput, 187  
 Indinavir, 1177  
 Indomethacin, 1417  
 Induction, 557, 1177  
 Inflammation, 64, 1779  
 Inhalation, 1485  
 Inhibition, 161, 537, 611, 1177  
 Insulin, 110, 452, 1071, 1474, 2008  
 Insulin absorption, 1551  
 Insulin transport, 1812  
 Integrity, 705  
 Intercellular adhesion molecule (ICAM), 1523  
 Interferon $\alpha_{2a}$ , 1721  
 Internalization, 1523  
 Intestinal absorption, 1163, 1192, 1200, 1210, 1674  
 Intestinal drug transport, 3, 373  
 Intestinal epithelium, 397, 1210  
 Intestinal exsorption, 910  
 Intestinal fluid, 900  
 Intestinal gene delivery, 569  
 Intestinal insulin delivery, 110  
 Intestinal metabolism, 745, 1591  
 Intestinal perfusion, 1163  
 Intestinal permeability, 448, 749  
 Intestinal secretion, 1192  
 Intestinal tract, 1071  
 Intestinal transport, 1184  
 Intestinal transporter, 1119, 1911  
 Intestine, 765, 1444, 1460, 1595  
 Intracellular, 1533  
 Intracellular fate, 221  
 Intracellular junction-associated proteins, 1838  
 Intracellular uptake, 212  
 Intradermal injections, 345  
 Intraduodenal administration, 552  
 Intragastric tablet performance, 2001  
 Infrared spectra, 1702  
 Intrinsic dissolution, 1641  
 Inulin, 303, 515  
 Ion channels, 3  
 Ion-pairs, 270, 597  
 Ionized drug molecules, 1317  
 Iontophoresis, 646, 653, 1496, 1612, 1946  
 Iontophoresis, reverse, 1508  
 Irinotecan, 910  
 Ischemia-perfusion injury, 1001  
 Islet transplantation, 1239  
 Isolation, 161  
 Isomaltodecaose, 873  
 Isoniazid, 1760  
 Isothiocyanate, 1351  
 Isradipine, 292  
 Itraconazole, 135, 810  
 Ivermectin, 1177
- J**  
 Japanese, 552  
 Jejunal permeability, 749  
 Jejunum, 1163  
 J-104132, 89  
 Juice, 169  
 Junction oncogenes, 1565
- K**  
 Ketoprofen, 187  
 Kidney, 1133  
 Kinetic analysis, 1200  
 Kinetic solvent isotopic effects, 1031  
 Kinetics, 368, 435  
 Kohlrausch-Williams-Watts equation, 1430, 1655  
*K<sub>pu</sub>* (plasma partition coefficients), 857, 864  
 KR-30031, 24  
 Kupffer cells, 1001, 1249
- L**  
 Lactam antibiotics, 1389  
 Lactonization, 1031  
 Lactose, amorphous, 1039  
 Lactulose, 429  
 Laser-induced pressure transients, 879  
 Laureate, 1267  
 LC-ESI/MS/MS analysis, 187  
 Lectin, 833  
 Lectin mimetics, 1258  
 Lepton, 169  
 Leptin, 1156  
 Leukocyte function-associated antigen-1, 1523  
 Levodopa, 1466  
 Ligand-binding assays, 1885  
 Ligand-specific targeting, 237  
 Light scattering, 479  
 Lime, 169  
 Lipid-binding sites, 1009  
 Lipid carriers, nanostructured, 1274  
 Lipid formulation, 1460  
 Lipid solubility, 639  
 Lipid transfer protein I, 1009  
 Lipoamino acids, 1697  
 Lipophilic drug delivery, 1085  
 Lipophilicity, 772, 864, 1317, 1946  
 Lipopolysaccharides, 81  
 Lipoprotein delivery systems, 738  
 Lipoproteins, 1009, 1085  
 Liposome/DNA complexes, 1452  
 Liposome uptake, 51  
 Liposomes, 229, 351, 442, 576, 1239, 1496, 1779  
 Liposomes, cationic, 962, 1452  
 Liposomes, epidermal growth factor, 229  
 Liposomes, folate receptor-targeted, 417  
 Liposomes, galatosylated, 1452  
 Liquid, 485  
 Liquid formulations, 1952  
 Liquid membranes, 1317  
 Liver, 81, 328, 745, 1452, 1600  
 Liver failure, 765  
 Liver perfusion, 81, 198  
 Liver preservation, 1001  
 Liver slices, 557  
 Liver-specific gene transfer, 328  
 LLC-PK<sub>1</sub> cells, 597, 1163
- Loading, 117  
 Lobe-selective gene transfer, 328  
 Local immunosuppression, 198  
 Log blood-brain values, 390  
 Long-chain alkyl mannosides, 51  
 Loperamide, 1163  
 Low concentration, 1417  
 Low-density lipoproteins, 126  
 LS180, 1177  
 Lubricant sensitivity, 515  
 Luciferase, 328  
 Luciferase assay, 1574  
 Lung, 2011  
 Lung cancer, 1908  
 Lung cancer cell lines, 1485  
 Lung deposition, 252  
 Lung deposition simulation, 442  
 Lung epithelial cell monolayers, 788  
 Lung resistance-related protein, 545  
 Lung surfactant, 1858  
 Lung transplant, 252  
 Luteinizing hormone-releasing hormone peptide, 889  
 Lymph, 1156  
 Lymphatic transport, 1460  
 Lymphocytes, 360  
 Lyophilization, 494  
 Lyophilized formulations, 873, 1655, 1952  
 Lysozyme, 303
- M**  
 M cells, 1258  
 Macromolecules, 1885  
 Macrophages, 51, 221, 962, 1249, 1533  
 MAD (maximum absorbable dose), 1149  
 Madin-Darby Canine Kidney (MDCK) cells, 319  
 Magnetic resonance imaging, seated, 2001  
 Mammalian intestinal transporter, 1911  
 Mannitol, 283, 660, 1690, 1939  
 Mannose receptor, 51  
 Mannosides, long-chain alkyl, 51  
 Markowitz profile, 996  
 Mass spectrometry, 275, 1820  
 Matrices, 988  
 Maximal flux, 1835  
 Maximum absorbable dose (MAD), 1149  
 MDCK (Madin-Darby Canine Kidney) cells, 319  
 MDR, *see* Multidrug resistance-associated proteins  
 Mean dissolution time, 406  
 Mechanistic studies, 569  
 Melanin binding, 1702  
 Melt extrusion, 1047  
 Memantine, 1702  
 Membrane, 779  
 Membrane binding, 624  
 Membrane-coated fibers, 275  
 Membrane penetration, 624  
 Mercaptopurine, 639  
 Mesochlorin  $e_6$  monoethylenediamine, 728  
 Mesoporous structure, 926  
 Metabolic rates, hepatic, 745  
 Metabolism, 757, 1681  
 Metabolism, cutaneous, 1113
- Metabolism, hepatic, 1591, 1600  
 Metabolism, intestinal, 1591  
 Methotrexate, 605, 1804  
 Methacrylated inulin hydrogels, 303  
 Methylphenidate, 1881  
 Methylprednisolone, 198, 1001  
 Metoprolol, 1141  
 Metoprolol tartrate, 1977  
 Mice, 328, 345, 368, 714, 728, 897, 904, 1163, 1293, 1713, 1846, 1908, 1995  
 Micelles, 297, 668, 1903, 2021  
 Micelles, polymeric, 2021  
 Micellization, 465  
 Microarrays, 3, 843  
 Microcalorimetry, 308, 465  
 Microdialysis, 605, 618, 1827  
 Microemulsion, 1460, 1772  
 Microemulsion formulations, 264, 1760  
 Microencapsulation, 1873  
 Microextraction, solid-phase, 337  
 Microfilter plate system, 96-well, 1317  
 Micronization, 485, 508, 2028  
 Microparticles, 221, 247, 788, 1533  
 Microplate screening system, 1170  
 Microscopy, atomic force, 479, 508, 804  
 Microscopy, confocal, 646  
 Microscopy, scanning electrochemical, 646  
 Microscopy, scanning electron, 479  
 Microspheres, 237, 452, 1055, 1846  
 Microspheres, uniform, 1055  
 Microthermal analysis, 135, 500  
 Midazolam, 187, 757  
 Midodrine hydrochloride, 1612  
 Minimum inhibitory concentration, 117  
 MITAT (moisture-induced thermal activity traces), 308  
 Mixed-anhydride, 205  
 Modeling, 143, 618  
 Modeling, cell handling, 624  
 Modeling, membrane binding, 624  
 Modeling, ocular pharmacokinetic, 1409  
 Modeling, pharmacogenomic, 996  
 Models, aerosol characterization, 788  
 Models, bioequivalence, 382  
 Models, cell culture, 373, 569  
 Models, continuous absorption, 1766  
 Models, dispersion, 1452  
 Models, human epidermis, 1113  
 Models, in vitro screening, 324  
 Models, microdialysis, 605  
 Models, nucleation, 1423  
 Models, oxidative damage, 684  
 Models, pharmacokinetic, 1156  
 Models, pharmacokinetic/pharmacodynamic, 1752  
 Models, physiologically based pharmacokinetic, 1766  
 Models, quantitative structure/activity relationship, 1401

- Models, remnant kidney, 1600  
 Models, 7-day, 96-well Caco-2, 1961  
 Models, solubility, 471  
 Models, stochastic, 996  
 Moisture, 1039  
 Moisture-induced thermal activity traces (MITAT), 308  
 Molconn-Z software, 1401  
 Molecular dispersions, 1417  
 Molecular dynamics simulation, 873  
 Molecular mobility, 1655  
 Monitoring, 435, 494  
 Monoclonal antibodies, 826  
 Monoclonal antibodies, fully human, 1952  
 Monte Carlo simulation, 988  
 Morphine, 618, 1474  
 Morphology, 1039  
 MRP (multidrug resistance-associated proteins), 31, 161, 324, 552, 904, 1119, 1394, 1581  
 Mucus, 569  
 Multidrug resistance, 161  
 Multidrug resistance-associated proteins (MRP), 31, 161, 324, 552, 904, 1119, 1394, 1581  
 Multidrug resistance protein 1 substrate drugs, 1163  
 Multidrug resistant human ovarian cancer cells, 351  
 Multiple antigenic peptide, 591  
 Muscarinic receptor subtypes, 1681  
 Mutagenesis, site-directed, 1911
- N**
- Nanocapsules, 1063, 1071, 1565  
 Nanoemulsion, 738, 1274  
 Nanofibers, drug-laden, 810  
 Nanoparticles, 110, 212, 409, 479, 674, 705, 833, 1772, 1786, 1812, 1864, 2011  
 Nanoparticles, antiestrogen-loaded, 1063  
 Nanoparticles, oil-loaded, 1274  
 Nanoparticles, polyester-polysaccharide, 1284  
 Nanoparticles, solid lipid, 1274  
 Nanospheres, 117, 584, 1565  
 Naproxen, 187  
 Nasal administration, 1225, 1474  
 Nasal epithelium, 153, 1125, 1690, 1838  
 Nebulization, 442, 2011  
 Neural retina, 1364  
 Neuronal cultures, 897  
 Neuropathic pain, 1752  
 Neurotoxicity, 937  
 Neutral lipid-binding sites, 1009  
 Nicotine, 1474  
 Nicotinic acid esters, 918  
 Nifedipine, 292  
 Nimesulide, 1485  
 Nimodipine, 292  
 N-in-one cocktails, 187  
 Nisoldipine, 292  
 Nitrendipine, 292  
 Nitric oxide synthase, 897  
 NMR (nuclear magnetic resonance), 465, 1634, 2174  
 Non-occlusive pretreatment, 653  
 Non-small-cell lung cancer cell lines, 1485  
 Noninvasive methods, 1508  
 Nonsteroidal anti-inflammatory drugs, 205  
 Nonviral gene transfer, 1779  
 Novel microemulsion enhancers, 264  
 Nrf2, 1351  
 Nuclear envelope, 879  
 Nuclear localization sequences, 728  
 Nuclear magnetic resonance (NMR), 465, 1274, 1634  
 Nuclear transport, 879  
 Nucleation, 797  
 Nucleation model, 1423  
 Nucleobase transport, 1804  
 Nucleoside transporters, 319, 1804  
 Nucleus, 1574  
 Nutrients, 1119
- O**
- Oatp3 (polypeptide subtype 3), 720  
 Occludin, 1838  
 Octanol-water distribution coefficient, 772  
 OCTN2 (organic cation transporter), 1133  
 Ocular absorption, 1409  
 Ocular bioavailability, 584  
 Ocular drug delivery, 96  
 Ocular irritation, 1697  
 Oil-loaded nanoparticles, 1274  
 Oleate, 1267  
 Oligonucleotides, antisense, 1565  
 Oligopeptide transporter, 1738  
 Oncogenes, 1565  
 Oponization, 1063  
 Oral absorption, 397, 1149, 1674, 1961  
 Oral administration, 1444, 1460  
 Oral-antigen delivery, 130  
 Oral bioavailability, 24, 448  
 Oral drug absorption, 397  
 Oral drug delivery, 931  
 Oral drug delivery system, 1989  
 Oral ingestion, 2001  
 Oral phosphate prodrugs, 848  
 Oral tolerance, 130  
 Oral vaccines, 1258  
 Organic anions, 1394  
 Organic cation-bile salt complexes, 597  
 Organic cation transporters, 1133  
 Organic solvents, 471  
 Ovalbumin, 130  
 Ovarian cancer, 351  
 Ovarian carcinoma cells, 728  
 Overexpression, 1581  
 Oxazolidinones, 1149  
 Oxidation, 684  
 Oxidative damage, 684  
 Oxybutinin, 103
- P**
- Paclitaxel, 24, 297, 957, 1022, 1302, 1864  
 Palmitoyl poly-L-lysine, 738  
 Paracellular pathway, 1984  
 Paracellular permeability, 153, 1838  
 Paracellular route, 397  
 Paracellular transport, 110  
 Paracetamol, 1668  
 Parallel artificial membrane permeability assay (PAMPA), 1820  
 Partial least squares, 1401  
 Partially unfolded states, 1721  
 Particle engineering, 485  
 Particle interactions, 508  
 Particle size, 1417  
 Particle size distribution, 1702  
 Particles, composite, 1039  
 Particles, reduced size, 1093  
 Partition coefficients, 275, 1502, 1858  
 Partitioning, 1317, 1634  
 PEG, *see* Polyethylene glycol  
 Pellets, 1970  
 Penetration, transdermal, 270  
 Penetration enhancement, 1267  
 Peptide stability, 1746  
 Peptide transporters, 1364, 1389, 1738, 1911  
 Peptides, targeted proapoptotic, 889  
 Percutaneous absorption, 143, 270, 275, 1113  
 Percutaneous permeation, 275  
 Perflubron, 16, 918  
 Perfluorocarbon emulsion, 1539  
 Perfusion, hepatic, 81, 198  
 Perfusion, intestinal, 1163  
 Permeability, 177, 187, 257, 390, 397, 448, 705, 749, 757, 848, 1149, 1357, 1820, 1917  
 Permeability, paracellular, 153  
 Permeability, passive, 1210  
 Permeability assays, 1961  
 Permeability enhancement, 1984  
 Permeabilization, 879  
 Permeation, 772, 1409, 1674  
 Permeation, percutaneous, 275  
 Permeation enhancer, 110  
 Permeation rates, 275  
 Personalized chemotherapy, 843  
*Pgp* substrates, 390  
 pH, 1721  
 pH, of buffers, 1437  
 pH dependency, 1141  
 pH-triggered release, 1533  
 Phagocytosis, 221, 237, 1539  
 Pharmaceutical solids, 531  
 Pharmaceuticals, 1325  
 Pharmacodynamic model, 1752  
 Pharmacodynamics, 937  
 Pharmacogenomics, 996  
 Pharmacokinetic model, 1156, 1752  
 Pharmacokinetics, 103, 252, 448, 552, 684, 857, 864, 1293  
 Pharmacokinetics, ocular, 1409  
 Pharmacokinetics, synovial fluid, 605  
 Pharmacology, cutaneous, 1113  
 Pharmacology, vitreoretinal, 576  
 Pharynx, 957  
 Phase diagrams, 264, 1661, 1939  
 Phase separation, 135, 1047  
 Phase transformation, 797  
 Phase transitions, 283, 802  
 Phenethyl isothiocyanates, 1351  
 Phenobarbital, 557  
 Phenothiazines, 1858  
 Phenylalanine, 1125  
 Phosphate ester, 848  
 Phosphatidylinositol, 126  
 Phosphorylation, 1838  
 Phosphoryloxymethyl prodrugs, 1031  
 Photodynamic therapy, 728  
 Photopolymer platform, 1730  
 Phthalimidomethylampicillin, 624  
 Physical properties, 1952  
 Physical stability, 1325  
 Physicochemical properties, 177, 962, 1274, 1474  
 Physiologic dissolution media, 1641  
 Pigs, 1170  
 Piroxicam, 1055  
 Pivampicillin, 624  
 Plasma lipoproteins, 126  
 Plasma partition coefficients (*K<sub>pu</sub>*), 857, 864  
 Plasma surface charge, 126  
 Plasmids, 328, 1452, 1730, 1779  
 Plasticizers, 1647  
 PLL-*g*-PEG (poly(L-lysine)-grafted-poly(ethylene glycol)), 237  
 Pluronic® block copolymers, 1085  
 Pluronic P85, 1581  
 Poly-L-arginine, 153, 1838  
 Poly(acryloyl-hydroxyethyl starch), 452  
 Poly(alpha-hydroxy acids), 149  
 Polyamidoamine dendrimers, 1543  
 Poly(butylcyanoacrylate), 409, 705  
 Polycarophil, thiolated, 931  
 Poly(cyanoacrylate), 674  
 Poly(epsilon-caprolactone), 1284  
 Polyester-poly(ethylene glycol) nanoparticles, 1063  
 Polyesters, branched, 2011  
 Poly(fumaric-co-sebacic anhydride), 1093  
 Poly(L-glutamic acid), 826  
 Polyethylene glycol, 668, 884, 1249, 1444  
 Polyethylene glycol 400, 1984  
 Polyethylene glycol coating, 584  
 Polyethylene glycol-coding, 962  
 Polyethylene glycol conjugation, 818  
 Polyethylene glycol lipids, 297  
 Polyethylene glycol spacers, 826  
 Poly(isobutylcyanoacrylate), 1071, 1786  
 Poly(L-lactic acid), 149  
 Poly(L-lactic-co-glycolic acid), 1846  
 Poly(lactide-co-glycolide), 147, 1055, 2011  
 Poly(D,L-lactide-co-glycolide), 452  
 Poly(D,L-lactide-co-glycolide) microspheres, 237, 884  
 Poly(D,L-lactide-co-glycolide) nanoparticles, 212  
 Poly(lactone), 668  
 Poly(L-lysine)-grafted poly(ethylene glycol) conjugates, 237  
 Polymer drug carriers, 1558  
 Polymer molecular weight, 1039  
 Polymer surface degradation, 149

- Polymerase chain reaction, real-time quantitative reverse transcription, 1373
- Polymeric carriers, 826
- Polymeric growth factor delivery, 1103
- Polymerization, 1786
- Polymers, 576, 884
- Polymers, biodegradable, 1864
- Polymers, thiolated, 1989
- Polymers, triblock, 2021
- Polymethacrylate, 1533
- Polymorph, 1939
- Polymorphic impurity determination, 1423
- Polymorphic transformation, 1926
- Polymorphism, 531, 552, 1851, 1939
- Polymorphs, 500
- Polymyxin B sulfate, 442
- Poly(p-dioxanone-co-L-lactide)-*block*-polyethylene glycol), 2021
- Polypeptide subtype 3 (rOat3), 720
- Polyphenols, 1258
- Polysaccharides, 1284, 1786
- Polysorbate 80, 1772
- Polysorbate-80-coated nanoparticles, 409
- Poly(vinylpyrrolidone), 1039, 1417
- Poorly water-soluble drugs, 1674
- Porcine brain capillary endothelial cells, 1170
- Pore transport, 646
- Porous material, 926
- Porous particles, silicon, 110
- Powder, 500
- Powder formulations, 969
- Powder mixtures, 804
- Powder particles, 500
- Power law, 988
- Precipitate, 73
- Prediction, 397, 471, 873, 1149, 1634, 1932
- Preservation, 2026
- Pressure transients, laser-induced, 879
- Primary neuronal culture, 897
- Probenecid, 618
- Procaine, 187
- Process analytical technology (PAT), 1851
- Prodrug activation, 423
- Prodrugs, 198, 205, 423, 448, 639, 772, 843, 848, 918, 1001, 1031, 1381
- Prodrugs, classic, 1558
- Prodrugs, starlike, 1558
- Progesterone receptor B isoform, 1574
- Prolong action, 205
- Propranolol, 187, 1496
- Proteases, 611, 1746
- Protein, carbonylated, 1713
- Protein, intracellular junction-associated, 1838
- Protein, micelle-associated, 1903
- Protein aggregation, 1325, 1873
- Protein binding, 857
- Protein binding, nonspecific, 1015
- Protein delivery, 435, 1156, 1231
- Protein effects, 848
- Protein efflux transporter, 161
- Protein formulation, 1903
- Protein oxidation, 1713
- Protein release, 303
- Protein stability, 1721
- Protein stabilization, 1873
- Protein structure, 1873
- Proteomics, 1373, 1713, 1721
- Proton-binding site, 1911
- Proton-coupled oligopeptide transporters, 1364
- Pulmonary absorption, 545, 1551
- Pulmonary drug delivery, 788, 1231
- Pummelo, 169
- Q**
- QTc, 1460
- Quantitative biopharmaceutics classification system, 1917
- Quantitative evaluation, 1163
- Quantitative gene expression, 1373
- Quantitative prediction, 1932
- Quantitative structure/activity relationship, 1401
- Quinidine, 1163
- R**
- R-apomorphine, 653
- Rabbits, 153, 1838
- Radical mechanisms, 1977
- Radioligand binding assay, 772
- Radiosterilization, 1977
- Ranitidine, 1984
- Rate constant measurements, 1977
- Rate of import, 1574
- Rats, 31, 58, 81, 198, 319, 448, 569, 611, 745, 765, 910, 937, 1001, 1071, 1133, 1231, 1293, 1373, 1452, 1496, 1568, 1591, 1607, 1766, 1779, 2008
- Reactive oxygen species, 962
- Reactivity, 292
- Receptor binding, 360, 1681
- Receptors, 417, 714, 1574
- Recombinant factor VIII, 693
- Recombinant human deoxyribonuclease (rhDNase), 2028
- Recovery, 1430
- Recursive partitioning, 1634
- Red blood cells, 1697
- ReGel™, 2008
- Regeneration, 1103
- Regional variation, 632
- Regulatory limits, 382
- Rehydration, 1926
- Relative humidity, 308
- Relaxation, 1430
- Release, 117
- Remnant kidney model, 1600
- Renal epithelium, 319
- Renal failure, 937, 1591
- Renal insufficiency, 1600
- Reservoir, 257
- Residual solvents, 337
- Retention, epidermal, 270
- Retinal endothelial cells, 1357
- Retinal pigment epithelial cells, 576, 1364
- Retinal pigment epithelium plasma membranes, 1364
- Retinoic acid, 1568
- Reversibility study, 1551
- Review, 337
- RGD-peptide, 237
- Rheumatoid arthritis, 605
- Rhodamine 123, 1177, 1192
- Rifampicin, 1760
- Ritalinic acid, 1881
- Ritonavir, 1163
- Rotigotine, 1619
- Ru 58668, 1063
- S**
- St. John's wort, 1177
- Salbutamol sulfate, 500
- Salbuterol sulfate particles, 508
- Salicylamide, 926
- Salicylic acid, 270
- Salmeterol xinafoate, 1423
- Salmon calcitonin, 73, 1989
- Sampling, 605
- Saturable uptake, 58
- Saturation, 1607
- Scaled average bioequivalence, 382
- Scavengers, 292
- Scintigraphy, gamma, 460, 1668, 1984
- Screening, 324
- Screening, in vitro, 1177
- SDS-PAGE (sodium-dodecylsulfate-polyacrylamide electrophoresis), 693
- Second virial coefficient, 1325
- Secondary ion mass spectrometry, 149
- Secretory transport, 1210
- SEDS™, 508
- Seizures, 937, 1293
- Sensitive drugs, 2026
- Sequestrants, 460
- Serially-passaged cultures, 1690
- Serine, 1838
- Serum, bovine albumin, 81, 303
- Sheep, 1156, 1474
- Shock waves, 879
- Sialic acid 9-*O*-acetyltransferase, 1309
- Signal transduction, 1351
- Silicon porous particles, 110
- Silver nanoparticle-enhanced fluorescence, 833
- Silymarin, 1184
- Simulation, 442, 873, 1752, 1766
- Simulation, Monte Carlo, 988
- Simultaneous surface analysis, 149
- SIRPα, 1539
- Sister-P-glycoprotein inhibitors, 537
- Site II, 684
- Site-specific conjugation, 818
- Size, of microspheres, 1055
- Skin, 16, 632, 646, 653, 1113, 1612, 1827
- Skin equivalent, 1113
- Skin irritation, 1496
- Skin penetration, 1267, 1619
- Skin penetration enhancement, 1502
- Skin permeability, 143, 257
- Slow-release, 1661
- Small intestine, 611, 1163, 1389, 1595, 1746
- SN-38, 910
- Sodium caprate, 110
- Sodium chloride, 660, 1939
- Sodium-dependent, purine-selective nucleoside transporters, 319
- Sodium laurate, 110
- Sodium phosphate buffers, 802
- Soft drugs, 1681
- Solid dispersion, 135
- Solid dosage forms, 460
- Solid form, 1952
- Solid-in-water encapsulation procedure, 1873
- Solid-phase microextraction, 337
- Solid polymorphism, 531
- Solid solutions, 1093
- Solid tumors, 417, 1337
- Solidification, 1926
- Solubility, 406, 471, 639, 797, 810, 918, 1149, 1626, 1760, 1820, 1917
- Solubility parameters, 1502
- Solubility prediction, 1634
- Solubilization, 1022, 1858
- Solubilizer, 1820
- Solution conformation, 1721
- Solution enthalpy, 471
- Solution stability, 693
- Solvents, organic, 471
- Solvents, residual, 337
- Sorting, 319
- Spacer length, 51
- Spacers, 826
- Spectrometry, mass, 275, 1820
- Spectrometry, secondary ion mass, 149
- Spectrophotometry, ultraviolet, 693
- Spectroscopy, Fourier-transform infrared, 632, 1267, 1926
- Spectroscopy, in-situ near-infrared, 494
- Spermine-Bowman-Birk inhibitor, 1908
- SPNT, 319
- Spray-drying, 1039, 1533
- Spray freeze-drying, 485, 969
- Stability, 308, 918, 1031, 1039, 1381, 1721, 1746, 1952
- Stabilization, 1437
- Starches, 452
- Starlike conjugate, 1558
- Stenlying effect, 674
- Stereochemistry, 1381
- Stereoselectivity, 1293
- Sterically-stabilized crystals, 297
- Sterically-stabilized micelles, 297
- Sterilization, 674, 2036
- Steroids, 177
- Storage, 308
- Strain, 257
- Stratum corneum, 632, 653, 1267, 1835
- Stress, 257
- Structure-activity relationship, 1022
- Subcellular compartmentalization, 728
- Subclones, 161
- Subcutaneous, 1156
- Substrate specificity, 745
- Substrates, fluorescent, 537
- Sucrose, 1647
- Sucrose esters, 1267

- Sugar glasses, 1437  
 Supercritical fluid technology, 508, 2028  
 Superoxide ions, electrogenerated, 292  
 Superparamagnetic contrast marker, 2001  
 Suppression, 351  
 Surface charge, 126  
 Surface engineering, 1543  
 Surface modification, 221, 237, 674  
 Surface tension, 797  
 Surfactant, 1858  
 Surfactants, 442, 653, 749, 1619, 1661, 1697  
 Surgery, 1591  
 Sustained release, 96, 212  
 Sustained retention, 212  
 Synergy, 957  
 Synovial fluid pharmacokinetics, 605  
 Systemic administration, 198
- T**
- Tablets, 460, 2001  
 Targeted proapoptotic peptide, 889  
 Targeting, 51, 64, 229, 303, 417, 423, 429, 826, 978, 1239, 1249, 1258, 1523, 1558  
 Targeting, ligand-specific, 237  
 Taste sensor, 1932  
 Taurodeoxycholate, 597  
 Taxol, 1864  
 T-cell epitopes, 591  
 T cells, 1523  
 Telomerase, 957  
 Telomeres, 957  
 Temperature, 1721  
 Terfenadine, 1177  
 Tetradecyl- $\beta$ -maltoside, 1551  
 Tetramethylaniline, 1317  
 Thermal analysis, 1423, 1926  
 Thermogravimetric analysis, 1926  
 Thermosensitive polymers, 884  
 Thermosensitivity, 1995  
 Thiolesterase, 1309  
 Thiomers, 931  
 Th1/Th2 balance, 130  
 Threonine, 1838  
 Thyroid hormone, 1568  
 Tight junction, 110  
 Tight junctions, 153, 1690, 1984  
 Timolol, 187, 1409, 1496, 1946  
 Tissue distribution, 857, 864  
 Tissue engineering, 1103, 1730  
 Tocophenyl polyethylene glycol 1000 succinate, 1864  
 Tocopherol, 368, 1846  
 Tolerance, oral, 130  
 Topical application, 16, 1502, 1827  
 Topical delivery, 639  
 Trace levels, 1423  
 Transcriptional activity, 1574  
 Transcriptional profiling, 843  
 Transcutol®, 1267  
 Transcytosis, 1231  
 Transdermal, 103, 1827  
 Transdermal delivery, 1496  
 Transdermal drug delivery, 257, 264, 1612, 1619, 1946  
 Transdermal extraction, 1508  
 Transdermal penetration, 270  
 Transdermal transport rate, 653  
 Transepidermal water loss, 632, 1267  
 Transepithelial electrical resistance, 169, 1690  
 Transepithelial transport, 1543  
 Transfection, 328, 738, 884, 2021  
 Transferrin, 1231  
 Transformed Potts-Guy equation, 639  
 Transnasal drug delivery systems, 1838  
 Transplantation, 1239  
 Transport, 177, 597, 714, 1794  
 Transport, absorptive, 1192, 1200, 1210  
 Transport, blood-brain barrier, 618  
 Transport, hepatobiliary, 89  
 Transport, paracellular, 110  
 Transport, secretory, 1210  
 Transport markers, 537  
 Transporter gene expression, 1119  
 Transporters, 3, 324  
 Transporters, amino acid, 1125  
 Transporters, organic cation, 1125  
 Transporters, probenecid-sensitive, 618  
 Trehalose, 500  
 Trehalose dihydrate, 1926  
 Triblock copolymers, 884, 1995, 2008  
 Triblock polymers, 2021  
 Tributylmethyl-ammonium, 597  
 Triciribine phosphate, 843  
 Triethylmethylammonium, 597  
 Trypsin, 611  
 Tuberculosis treatment, 1760  
 Tumor cells, 738, 1249  
 Tumor growth factor- $\beta$ 1, 345, 1995  
 Tumor-specific antibody, 1249  
 Tumor targeting, 229  
 Tumors, 1337  
 Tumors, solid, 417  
 Tween 80, 797, 1015, 1903  
 Two-electrode voltage lamp, 1911  
 2/4/A1 cell monolayers, 373, 397  
 Tyrosine phosphatase, 1838
- U**
- Ulex europaeus* agglutinin 1, 1258  
 Ultrafiltration, 1015  
 Ultramicrotomy, 479  
 Unit dose, 1460  
 Uptake, 58, 714, 1225, 1389, 1812  
 Uptake, saturable, 58  
 Uptake screening, 1738  
 Uridine diphosphate-glucuronosyltransferase, 1568
- V**
- Vaccines, 247, 969  
 Vaccines, DNA, 16  
 Vaccines, oral, 1258  
 Valnoctamide, 1293  
 Valproate, 1508  
 Valproic acid, 1293  
 Valpromide, 1293  
 Vascular smooth muscle cells, 212  
 Vasoconstrictors, 270  
 Vectors, nonviral, 569  
 Vehicle effects, 639  
 Vehicle pretreatment, 1502  
 Verapamil, 187, 1163, 1177  
 Villin, 324  
 Vinblastine, 38, 1163, 1184, 1581, 1607  
 Vincristine, 904  
 Viscosity, 1952  
 Vitamin E, 292  
 Vitreous, 576  
 Vitreous humor, 96  
 Voltammetry, cyclic, 1317  
 Voltammetry, differential pulse, 292  
 Volunteers, healthy, 1466
- W**
- Water-based surfactants, 653  
 Water-in-oil emulsion, 130  
 Water-insoluble drugs, 297  
 Water loss, 632  
 Water loss, transepidermal, 1267  
 Water-oil partition profiling, 1317  
 Water solubility, 639, 797  
 Water-soluble boronated acridine, 229  
 Water-soluble drugs, 810, 1022, 1093, 1674  
 Water vapor interactions, 308  
 Wax, 1772  
 Weibull function, 988  
 Western blot, 1373  
 Wet granulation, 1851  
 Wheat germ agglutinin, 833  
 W/O emulsion, 130  
 Work, of adhesion, 508  
 Wound healing, 345, 884, 1995
- X**
- X-ray fluorescence (XRF), 435  
 X-ray powder diffraction, online, 1851  
 X-ray powder diffractometry, 283  
 Xenobiotic bioconversion, 1113  
 Xenografts, 417  
*Xenopus* oocytes, 1911  
 XRF (x-ray fluorescence), 435
- Z**
- Zero-order release, 1055  
 Zinc modulation, 1389  
 ZO-1 protein, 1838  
 Zwitterionic surfactants, 1697